Tenet Healthcare Corporation

▲ Bull Case

• ◆USPI multiple re-rating is mechanical—SGRY trades 14–16x EBITDA; USPI's $1.55B (FY 2024E) → $2.02B (FY 2026E) EBITDA is 4–5x SGRY's size with higher 37%+ margins and 7–8% same-facility growth; at 14x, USPI alone worth $27B+ vs THC's ~$29B total EV—entire hospital+Conifer priced near zero.
• ◆Deleveraging path enables credit re-rating—net debt fallen from $14.7B (FY 2023) → ~$11B (Q1 2026) to <$10B (FY 2026) and <$7B (FY 2028); at 2.5x net leverage qualifies for BBB-/Baa3 investment-grade credit, lowering interest costs ~$100M annually and expanding institutional shareholder base.
• ◆EPS torque from buybacks—diluted shares fallen from ~120M (FY 2019) → ~88M (Q1 2026) to ~76M (FY 2029); combined with EBITDA growth + interest reduction drives EPS from ~$10.90 (FY 2025E) → ~$22 (FY 2029E).

▼ Bear Case

• ◆Medicaid funding cuts (2025–2026 budget cycle) are binary, unhedgeable risk—Medicaid ~15% of Hospital revenue, concentrated in Texas/Florida; Republican proposals include $100B+ cuts; $200M EBITDA hit = ~$1/EPS and ~$15–20 share price impact plus structural multiple compression.
• ◆GLP-1 drugs may compress USPI volumes faster—USPI requires 7–9% same-facility growth; bariatric and orthopedic joint replacement (~25–30% of cases) most exposed to GLP-1 adoption; GLP-1 prescription base grown 100%+ in 2024–2026; 5% volume haircut takes ~$90/share off SOTP value.
• ◆Refinancing wall meets credit-cycle risk—$3–4B senior notes mature 2027–2028; if IG upgrade delayed by Medicaid hit, spreads widen on regulatory uncertainty, or Fed cuts disappoint, refinancing cost spikes $50–100M annually, stalling leverage at 3.3–3.5x.

“Street consensus 'Buy/Moderate Buy' with ~$244 price target (19 Buy, 3 Hold). Debate is not company quality but what multiple USPI deserves embedded in hospital chassis. Bulls argue 14–16x SGRY-equivalent (implies $300+ THC), bears argue 10–12x 'embedded ASC inside hospital company' multiple (~$200 THC). Secondary debate: how much Medicaid policy risk is already priced vs. still live overhang. Tertiary: whether current buybacks at $175+ are accretive vs. debt reduction.”

• ◆USPI same-facility growth Q2–Q4 2026—if sustained at 7–9% removes GLP-1 overhang, confirms re-rating path
• ◆2025–2026 Congressional Medicaid policy resolution—binary event, either removes overhang or materializes bear case
• ◆Net leverage crossing 3.0x and 2.5x milestones—triggers credit rating agency review for investment-grade upgrade
• ◆Hospital divestiture announcements at 7–8x EBITDA pricing—proves M&A market access, accelerates leverage path
• ◆FY 2027 guidance issuance—first explicit framing of USPI as majority-EBITDA business
• ◆Conifer IPO/spin announcement—unlocks $1.5–2B embedded value
• ◆Investment-grade credit rating upgrade—interest savings plus new institutional buyers

• ◆Medicaid policy cuts ($200M+ EBITDA hit)—high severity, medium probability; ~$15–25/share direct downside
• ◆GLP-1 volume disruption (5%+ USPI case decline)—medium-high severity, low-medium probability; ~$60–90/share downside via SOTP
• ◆Hospital labor cost re-acceleration—high severity if occurs, low probability; each 1% labor inflation = ~$80M EBITDA hit
• ◆DOJ/legal investigation re-surfaces—high severity if material, low probability latent risk
• ◆CEO Sutaria departure—high severity, low probability; strategy and execution heavily tied to him
• ◆Refinancing risk on 2027–2028 notes—medium severity, low-medium probability
• ◆PE-backed independent ASC competition for top surgeons—medium severity, medium probability, 2–5 year horizon